This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through March 4, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Zacks News
Arcellx (ACLX) Up 5% on Partnership Expansion With Gilead
by Zacks Equity Research
Arcellx (ACLX) and Gilead (GILD) expand their existing collaboration in cancer treatment. This deal is expected to close by year-end.
Is Biohaven Ltd. (BHVN) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Biohaven Ltd. (BHVN) and Blueprint Medicines (BPMC) have performed compared to their sector so far this year.
BioCardia (BCDA) Soars 168% on FDA Nod to Heart Failure Study
by Zacks Equity Research
The FDA approves BioCardia's (BCDA) phase III study on its CardiAMP cell therapy to treat patients with ischemic heart failure.
Aclaris (ACRS) Lead Drug Fails Rheumatoid Arthritis Study
by Zacks Equity Research
Aclaris (ACRS) decides to stop the development of its lead drug after top-line data from a mid-stage study did not achieve any study goals. Shares plunge 86% following the news.
Novavax (NVAX) Beats on Q3 Earnings & Sales, Cuts Sales View
by Zacks Equity Research
Novavax (NVAX) reports better-than-expected third-quarter results, with earnings and revenues beating estimates. It lowers product sales guidance for 2023.
Jazz (JAZZ) Lags Q3 Earnings, Beats Sales, Raises '23 View
by Zacks Equity Research
Jazz (JAZZ) reports mixed results in third-quarter 2023. However, shares rose 2.5% post the announcement, likely on the back of raised guidance for 2023.
Biohaven Ltd. (BHVN) Is a Great Choice for 'Trend' Investors, Here's Why
by Zacks Equity Research
If you are looking for stocks that are well positioned to maintain their recent uptrend, Biohaven Ltd. (BHVN) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Are Medical Stocks Lagging Biohaven Ltd. (BHVN) This Year?
by Zacks Equity Research
Here is how Biohaven Ltd. (BHVN) and Blueprint Medicines (BPMC) have performed compared to their sector so far this year.
Merck (MRK) Inks Deal With Daiichi to Develop Cancer Drugs
by Zacks Equity Research
Per the terms, Merck (MRK) and Daiichi Sankyo will develop and market three ADC drugs to treat multiple types of cancer. Following the execution, Merck will make an upfront payment of $4 billion.
Here's Why Momentum in Biohaven Ltd. (BHVN) Should Keep going
by Zacks Equity Research
Biohaven Ltd. (BHVN) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Walgreens (WBA) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Continued strategic executions on the United States and the international fronts are likely to drive Walgreens (WBA) Q4 revenues.
Here's What Could Help Biohaven Ltd. (BHVN) Maintain Its Recent Price Strength
by Zacks Equity Research
If you are looking for stocks that are well positioned to maintain their recent uptrend, Biohaven Ltd. (BHVN) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Biohaven (BHVN) Up on Positive Data from Autoimmune Disease Drug
by Zacks Equity Research
Biohaven (BHVN) gains on preliminary data from a pre-clinical study on its pipeline candidate BHV-1300 targeting various autoimmune diseases.
Biotech Stock Roundup: MRNA's Vaccine Update, AMGN & HZNP Clear FTC Lawsuit & More
by Zacks Equity Research
Pipeline and regulatory updates from (MRNA) and Amgen (AMGN) are in focus in the biotech sector.
Biohaven (BHVN) Stock up 8% on Encouraging Pipeline Updates
by Zacks Equity Research
At its R&D Day, Biohaven (BHVN) provides updates on its pipeline. It also announced submission of a regulatory filing seeking approval for troriluzole in SCA3, an ultra-rare disorder.
Is Biohaven Ltd. (BHVN) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Biohaven Ltd. (BHVN) and Hologic (HOLX) have performed compared to their sector so far this year.
Biohaven (BHVN) Acquires Dual Inhibitor for Brain Disorders
by Zacks Equity Research
Biohaven (BHVN) has acquired an exclusive license for dual Inhibitor of TYK2/JAK1 for the pre-clinical study of immune-mediated brain disorders.
Pfizer (PFE) Gets FDA Nod for Migraine Nasal Spray Zavzpret
by Zacks Equity Research
Zavzpret (zavegepant) is now part of Pfizer's (PFE) migraine drugs portfolio with the 2022 acquisition of Biohaven. Zavzpret provides migraine patients access to a fast-acting pain-relief option.
Why Earnings Season Could Be Great for Biohaven (BHVN)
by Zacks Equity Research
Biohaven (BHVN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Should Vanguard Russell 2000 ETF (VTWO) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for VTWO
Is Biohaven Ltd. (BHVN) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Biohaven Ltd. (BHVN) and Clover Health Investments, Corp. (CLOV) have performed compared to their sector so far this year.
Should iShares Russell 2000 ETF (IWM) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for IWM
After Plunging 13% in 4 Weeks, Here's Why the Trend Might Reverse for Biohaven Ltd. (BHVN)
by Zacks Equity Research
Biohaven Ltd. (BHVN) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
How Much Upside is Left in Biohaven Ltd. (BHVN)? Wall Street Analysts Think 54%
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 53.5% in Biohaven Ltd. (BHVN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Biohaven Ltd. (BHVN) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Biohaven Ltd. (BHVN) delivered earnings and revenue surprises of 30.83% and 100%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?